EICHOR
● Completed
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Condition: Cardiac Amyloidosis · AL Amyloidosis · ATTR Amyloidosis · Sponsor: Lantheus Germany GmbH
About this study
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (14)
| St Luke's Hospital | Kansas City, Kansas, United States | — |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | — |
| University of Augsburg | Augsburg, Germany | — |
| Charite Berlin | Berlin, Germany | — |
| University of Essen | Essen, Germany | — |
| HOPA Hamburg | Hamburg, Germany | — |
| University of Heidelberg | Heidelberg, Germany | — |
| University of Würzburg | Würzburg, Germany | — |
| Hospital University Bellvitge | Barcelona, Spain | — |
| Hospital University Puerta de Hierro | Madrid, Spain | — |
| Clínica Universidad de Navarra | Pamplona, Spain | — |
+ 2 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05184088